37 related articles for article (PubMed ID: 32929802)
1. Hepatitis C Clearance by Direct-Acting Antivirals Impacts Glucose and Lipid Homeostasis.
Graf C; Welzel T; Bogdanou D; Vermehren J; Beckel A; Bojunga J; Friedrich-Rust M; Dietz J; Kubesch A; Mondorf A; Fischer S; Lutz T; Stoffers P; Herrmann E; Poynard T; Zeuzem S; Dultz G; Mihm U
J Clin Med; 2020 Aug; 9(9):. PubMed ID: 32825571
[TBL] [Abstract][Full Text] [Related]
2. Triglyceride-rich lipoproteins and insulin resistance in patients with chronic hepatitis C receiving direct-acting antivirals.
Casas-Deza D; Espina S; Martínez-Sapiña A; Del Moral-Bergos R; Garcia-Sobreviela MP; Lopez-Yus M; Calmarza P; Bernal-Monterde V; Arbones-Mainar JM
Atherosclerosis; 2023 Jun; 375():59-66. PubMed ID: 37245427
[TBL] [Abstract][Full Text] [Related]
3. Real-Life Early Anthropometric, Lipid and Liver Changes after Direct-Acting Antiviral Therapy in PLWHIV with HCV Co-Infection.
Ferra-Murcia S; Collado-Romacho AR; Nievas-Soriano BJ; Reche-Lorite F; Parrón-Carreño T
J Clin Med; 2022 May; 11(9):. PubMed ID: 35566765
[TBL] [Abstract][Full Text] [Related]
4. Lipid Profile and Cardiovascular Risk Modification after Hepatitis C Virus Eradication.
Pascual-Oliver A; Casas-Deza D; Yagüe-Caballero C; Arbones-Mainar JM; Bernal-Monterde V
Pathogens; 2024 Mar; 13(4):. PubMed ID: 38668233
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C is now curable, but what happens with cirrhosis and portal hypertension afterwards?
Grgurevic I; Bozin T; Madir A
Clin Exp Hepatol; 2017 Dec; 3(4):181-186. PubMed ID: 29255805
[TBL] [Abstract][Full Text] [Related]
6. PPARγ activation improves the microenvironment of perivascular adipose tissue and attenuates aortic stiffening in obesity.
Chen JY; Wu YP; Li CY; Jheng HF; Kao LZ; Yang CC; Leu SY; Lien IC; Weng WT; Tai HC; Chiou YW; Tang MJ; Tsai PJ; Tsai YS
J Biomed Sci; 2021 Mar; 28(1):22. PubMed ID: 33781257
[TBL] [Abstract][Full Text] [Related]
7. Atrial high‑rate episodes and risk of major adverse cardiovascular events in patients with dual chamber permanent pacemakers: a retrospective study.
Lu WD; Chen JY
Sci Rep; 2021 Mar; 11(1):5753. PubMed ID: 33707593
[TBL] [Abstract][Full Text] [Related]
8. Effects of sustained viral response on lipid in Hepatitis C: a systematic review and meta-analysis.
Mei T; Huang X; Tang S; Liu M; Zhang W; Yu H
Lipids Health Dis; 2024 Mar; 23(1):74. PubMed ID: 38461262
[TBL] [Abstract][Full Text] [Related]
9. A Comparative Study on the Presence and Reversibility of Subclinical Arterial Damage in HCV-Infected Individuals and Matched Controls.
Androutsakos T; Mouziouras D; Katelani S; Psichogiou M; Sfikakis PP; Protogerou AD; Argyris AA
Viruses; 2023 Jun; 15(6):. PubMed ID: 37376673
[No Abstract] [Full Text] [Related]
10. The Impact of Steatosis on Chronic Hepatitis C Progression and Response to Antiviral Treatments.
Siphepho PY; Liu YT; Shabangu CS; Huang JF; Huang CF; Yeh ML; Yu ML; Wang SC
Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680608
[TBL] [Abstract][Full Text] [Related]
11. Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update.
Roguljic H; Nincevic V; Bojanic K; Kuna L; Smolic R; Vcev A; Primorac D; Vceva A; Wu GY; Smolic M
Front Pharmacol; 2021; 12():678546. PubMed ID: 34045969
[TBL] [Abstract][Full Text] [Related]
12. Augmenting central arterial stiffness following eradication of HCV by direct acting antivirals in advanced fibrosis patients.
Cheng PN; Chen JY; Chiu YC; Chiu HC; Tsai LM
Sci Rep; 2019 Feb; 9(1):1426. PubMed ID: 30723238
[TBL] [Abstract][Full Text] [Related]
13. Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy.
Tada T; Kumada T; Toyoda H; Sone Y; Takeshima K; Ogawa S; Goto T; Wakahata A; Nakashima M; Nakamuta M; Tanaka J
Aliment Pharmacol Ther; 2018 Apr; 47(7):1012-1022. PubMed ID: 29424449
[TBL] [Abstract][Full Text] [Related]
14. Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
Tada T; Kumada T; Toyoda H; Mizuno K; Sone Y; Kataoka S; Hashinokuchi S
J Gastroenterol Hepatol; 2017 Dec; 32(12):1982-1988. PubMed ID: 28299813
[TBL] [Abstract][Full Text] [Related]
15. Magnitude and Kinetics of Decrease in Liver Stiffness After Antiviral Therapy in Patients With Chronic Hepatitis C: A Systematic Review and Meta-analysis.
Singh S; Facciorusso A; Loomba R; Falck-Ytter YT
Clin Gastroenterol Hepatol; 2018 Jan; 16(1):27-38.e4. PubMed ID: 28479504
[TBL] [Abstract][Full Text] [Related]
16. Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy.
Drazilova S; Gazda J; Janicko M; Jarcuska P
Can J Gastroenterol Hepatol; 2018; 2018():6150861. PubMed ID: 30186821
[TBL] [Abstract][Full Text] [Related]
17. Persistent augmentation of central arterial stiffness following viral clearance by direct-acting antivirals in chronic hepatitis C.
Chen JY; Cheng PN; Chiu YC; Chiu HC; Tsai WC; Tsai LM
J Viral Hepat; 2021 Jan; 28(1):159-167. PubMed ID: 32929802
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
